YolTech Therapeutics Secures $45 Million in Series B Funding to Advance Gene-Editing Therapies#China#Shanghai#YolTech_Therapeutics#gene-editing#AstraZeneca-CICC
YolTech Therapeutics Secures $45 Million in Series B Funding to Advance Gene-Editing Therapies
YolTech Therapeutics has successfully raised $45 million in Series B funding, led by AstraZeneca-CICC, to progress its innovative gene-editing therapies.
third-news.com
September 11, 2025 at 12:27 PM
YolTech Therapeutics Secures $45 Million in Series B Funding to Advance Gene-Editing Therapies#China#Shanghai#YolTech_Therapeutics#gene-editing#AstraZeneca-CICC
YolTech Therapeutics Unveils Promising Results for YOLT-203, Targeting Primary Hyperoxaluria Type 1#China#Shanghai#YOLT-203#YolTech_Therapeutics#PH1
YolTech Therapeutics Unveils Promising Results for YOLT-203, Targeting Primary Hyperoxaluria Type 1
YolTech Therapeutics shares encouraging data on YOLT-203, an innovative gene-editing treatment for Primary Hyperoxaluria Type 1, showcasing safety and efficacy.
third-news.com
February 25, 2025 at 8:20 AM
YolTech Therapeutics Unveils Promising Results for YOLT-203, Targeting Primary Hyperoxaluria Type 1#China#Shanghai#YOLT-203#YolTech_Therapeutics#PH1
YolTech Therapeutics Launches Exciting Gene Editing Clinical Trial for β-Thalassemia#China#Shanghai#YolTech_Therapeutics#YOLT-204#β-Thalassemia
YolTech Therapeutics Launches Exciting Gene Editing Clinical Trial for β-Thalassemia
YolTech Therapeutics embarks on a significant clinical trial for YOLT-204, an innovative gene therapy targeting β-thalassemia, aiming for curative outcomes.
third-news.com
January 21, 2025 at 2:38 AM
YolTech Therapeutics Launches Exciting Gene Editing Clinical Trial for β-Thalassemia#China#Shanghai#YolTech_Therapeutics#YOLT-204#β-Thalassemia